| Literature DB >> 36011389 |
Seyyed Fatemeh Hosseini1, Khalil Khashei Varnamkhasti1, Raziyeh Naeimi2, Leila Naeimi1, Sirous Naeimi1.
Abstract
BACKGROUND: Additional inflammatory responses and subsequent damage-arising from enhance transcriptional activity or forming the more active protein due to existence of polymorphic sites in the pro-inflammatory cytokines gene loci-give rise to myocardial infarction susceptibility.Entities:
Keywords: IL-13 +2044G/A; IL-13 −1512A/C; Interleukin-13 gene; myocardial infarction; polymorphism
Mesh:
Substances:
Year: 2022 PMID: 36011389 PMCID: PMC9408623 DOI: 10.3390/genes13081478
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.141
Demographic characteristics of MI patients and controls.
| Variables | MI Patients | Controls | |
|---|---|---|---|
| N = (250) | N = (250) | ||
| Age, years | 57.54 ± 8.51 | 57.82 ± 8.07 | 0.239 |
| range | 33–70 | 35–70 | - |
| Sex (Men) | 129 | 129 | 0.142 |
| Hypertension n (%) | 148 (59.2) | - | - |
| Hypercholesterolemia n (%) | 192 (76.8) | - | - |
| Hyperglycemia n (%) | 167 (66.8) | - | - |
| Coronary artery disease n (%) | 148 (42.8) | - | - |
Genotype frequency distributions of −1512A/C and +2044G/A polymorphisms in MI patients and controls.
|
| MI Patients | Controls | |
|---|---|---|---|
| rs1881457 (−1512A/C) | |||
| AA | 147 (58.8) | 120 (48) | 0.031 |
| AC | 92 (36.8) | 110 (44) | |
| CC | 11 (4.4) | 20 (8) | |
| rs20541 (+2044G/A) | |||
| GG | 136 (54.4) | 121 (48.4) | 0.349 |
| GA | 90 (36) | 98 (39.2) | |
| AA | 24(9.6) | 31 (12.4) |
Associations of −1512A/C and +2044G/A polymorphisms and the development of myocardial infraction risk factors.
|
|
| ||
|
|
|
| |
| rs1881457 (−1512A/C) | |||
| Hypercholesterolemia | |||
| >200 mg | 122 (48.8) | 63 (25.2) | 7 (2.8) |
| <200 mg | 25 (10) | 29 (11.6) | 24 (1.6) |
| Sig. (Exp. (B)) | 0.041 (2.779) | 0.010 (2.246) | 0.000 (0.205) |
| Hyperglycemia | |||
| >140 mg | 112 (44.8) | 47 (18.8) | 8 (3.2) |
| <140 mg | 35 (10) | 45 (11.6) | 3 (1.6) |
| Sig. (Exp. (B)) | 0.016 (3.036) | 0.010 (1.246) | 0.043 (0.205) |
| Hypertension | |||
| Yes | 95 (38) | 51 (20.4) | 2 (8) |
| No | 52 (20.8) | 41 (16.4) | 9 (4.5) |
| Sig. (Exp. (B)) | 0.008 (8.221) | 0.015 (1.465) | 0.000 (0.547) |
| Coronary artery disease | |||
| Yes | 115 (46) | 26 (10.4) | 2 (8) |
| No | 32 (12.8) | 66 (26.4) | 9 (3.6) |
| Sig. (Exp. (B)) | 0.001 (0.062) | 0.000 (0.010) | 0.000 (0.593) |
| Genetic ancestry | |||
| Yes | 144 (57.6) | 78 (85.4) | 10 (4) |
| No | 3 (20.8) | 14 (16.4) | 1 (4.5) |
| Sig. (Exp. (B)) | 0.001 (8.671) | 0.012 (4.850) | 0.018 (0.21) |
|
|
| ||
|
|
|
| |
| rs20541(+2044G/A) | |||
| Hypercholesterolemia | |||
| >200 mg | 93 (37.2) | 80 (32) | 19 (7.6) |
| <200 mg | 43 (48.4) | 10 (39.2) | 5 (12.4) |
| Sig. (Exp. (B)) | 0.029 (1.757) | 0.021(0475) | 0.008 (0.263) |
| Hyperglycemia | |||
| >140 mg | 79 (31.6) | 70(28) | 18 (7.2) |
| <140 mg | 57 (22.8) | 20(8) | 6 (2.4) |
| Sig. (Exp. (B)) | 0.012 (2.165) | 0.077 (0.857) | 0.020 (0.333) |
| Hypertension | |||
| Yes | 71 (28.4) | 62 (24.8) | 15 (6) |
| No | 65 (22.8) | 28 (11.2) | 9 (3.6) |
| Sig. (Exp. (B)) | 0.035 (1.526) | 0.055(0.753) | 0.022 (0.600) |
| Coronary artery disease | |||
| Yes | 75 (30) | 15(6) | 17 (6.8) |
| No | 61 (24.4) | 75(30) | 7 (2.8) |
| Sig. (Exp. (B)) | 0.013 (1.975) | 0.000 (0.857) | 0.048 (0.412) |
| Genetic ancestry | |||
| Yes | 128 (51.2) | 66 (26.4) | 0 (0) |
| No | 8 (3.2) | 24 (9.6) | 24 (9.6) |
| Sig. (Exp. (B)) | 0.019 (2.685) | 0.006 (0.057) | 0.009 (0.5) |
Sig.: significant; Exp. (B): exponentiation of the B coefficient.